Trough concentrations of lopinavir, nelfinavir, and nevirapine with standard dosing in human immunodeficiency virus-infected pregnant women receiving 3-drug combination regimens

Therapeutic Drug Monitoring

Volumn 30, Issue 5, 2008, Pages 604-610

  Baroncelli, Silvia ^a   Villani, Paola ^b   Floridia, Marco ^a   Pirillo, Maria F ^a   Galluzzo, Clementina M ^a   Cusato, Maria ^b   Amid, Roberta ^a   Pinnetti, Carmela ^c   Sabbatini, Francesca ^d   Molinari, Atim ^e   Tamburrini, Enrica ^c   Regazzi, Mario ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^e UNIVERSITY HOSPITAL OF PARMA   (Italy)

Author keywords

HIV infection; Lopinavir; Nelfinavir; Nevirapine; Pharmacokinetics; Pregnancy; Therapeutic drug monitoring

Indexed keywords

ABACAVIR; DIDANOSINE; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; STAVUDINE; TENOFOVIR; ZIDOVUDINE; PYRIMIDINONE DERIVATIVE;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; FEMALE; GENETIC RESISTANCE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PREGNANT WOMAN; PRIORITY JOURNAL; THIRD TRIMESTER PREGNANCY; TREATMENT DURATION; VIRUS LOAD; ADOLESCENT; BLOOD; COHORT ANALYSIS; COMPARATIVE STUDY; COMPLICATION; DRUG COMBINATION; HIV INFECTIONS; PHYSIOLOGY; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; STANDARDS; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HUMANS; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PYRIMIDINONES; VIRAL LOAD; YOUNG ADULT;

EID: 55349087596     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181867a6e     Document Type: Article

References (38)

1. Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29:484-494.
2. Thorne C, Newell ML. HIV. Semin Fetal Neonatal Med. 2007;12:174-181.
3. Acosta EP, Zorrilla C, Van Dyke R, et al. Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. HIV Clin Trials. 2001;2:460-465.
4. Tracy TS, Venkataramanan R, Glover DD, et al. Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy. Am J Obstet Gynecol. 2005;192:633-639.
5. Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. AIDS. 2006;20:1931-1939.
6. Villani P, Floridia M, Pirillo MF, et al. Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women. Br J Clin Pharmacol. 2006;62:309-315.
7. Unadkat JD, Wara DW, Hughes MD, et al. Pharmacokinetics and safety of indinavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother. 2007;51:783-786.
8. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. January 29, 2008. Available at: http://aidsinfo.nih.gov/ contentfiles/AdultandAdolescentGL.pdf. Accessed August 18, 2008.
9. Floridia M, Tamburrini E, Ravizza M, et al. Antiretroviral therapy at conception in pregnant women with HIV in Italy: wide range of variability and frequent exposure to contraindicated drugs. Antivir Ther. 2006;11:941-946.
10. Pellegrin I, Breilh D, Montestruc F, et al. Virologic response to nelfinavirbased regimens: pharmacokinetics and drug resistance mutations (VIRAPHAR study). AIDS. 2002;16:1331-1340.
11. Burger DM, Hugen PW, Aarnoutse RE, et al. Treatment failure of nelfinavir-containing triple therapy can largely be explained by low nelfinavir plasma concentrations. Ther Drug Monit. 2003;25:73-80.
12. Breilh D, Pellegrin I, Rouzes A, et al. Virological, intracellular and plasma pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR study). AIDS. 2004;18:1305-1310.
13. la Porte CJL, Back DJ, Blaschke T et al. Updated guidelines to perform therapeutic drug monitoring for antiretroviral agents. Rev Antiviral Ther. 2006;3:4-14.
14. Veldkamp AI, Weverling GJ, Lange JM, et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS. 2001;15:1089-1095.
15. Kappelhoff BS, Crommentuyn KM, de Maat MM, et al. Practical guidelines to interpret plasma concentrations of antiretroviral drugs. Clin Pharmacokinet. 2004;43:845-853.
16. van Leth F, Kappelhoff BS, Johnson D, et al. Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy. AIDS Res Hum Retroviruses. 2006;22:232-239.
17. Moyer TP, Temesgen Z, Enger R, et al. Drug monitoring of antiretroviral therapy for HIV-1 infection: method validation and results of a pilot study. Clin Chem. 1999;45:1465-1476.
18. van Heeswijk RP, Hoetelmans RM, Meenhorst PL, et al. Rapid determination of nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection. J Chromatogr B Biomed Sci Appl. 1998;713:395-399.
19. Marzolini C, Telenti A, Decosterd LA, et al. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS. 2001;15:71-75.
20. Van Heeswijk RP. Critical issues in therapeutic drug monitoring of antiretroviral drugs. Ther Drug Monit. 2002;24:323-331.
21. Krauer B, Krauer F, Hytten FE. Drug disposition and pharmacokinetics in the maternal-placental-fetal unit. Pharmacol Ther. 1980;10:301-328.
22. Anderson GD. Pregnancy-induced changes in pharmacokinetics: a mechanistic-based approach. Clin Pharmacokinet. 2005;44:989-1008.
23. Dawes M, Chowienczyk PJ. Drugs in pregnancy. Pharmacokinetics in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2001;15:819-826.
24. Kosel BW, Beckerman KP, Hayashi S, et al. Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women. AIDS. 2003; 17:1195-1199.
25. Timmermans S, Tempelman C, Godfried MH, et al. Nelfinavir and nevirapine side effects during pregnancy. AIDS. 2005;19:795-799.
26. European Collaborative Study; Patel D, Cortina-Borja M, Thorne C, et al. Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clin Infect Dis. 2007;44:1647-1656.
27. Mirochnick M, Fenton T, Gagnier P, et al. Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. J Infect Dis. 1998;178:368-374.
28. Musoke P, Guay LA, Bagenda D, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS. 1999;13:479-486.
29. Gingelmaier A, Kurowski M, Kastner R, et al. Placental transfer and pharmacokinetics of lopinavir and other protease inhibitors in combination with nevirapine at delivery. AIDS. 2006;20:1737-1743.
30. von Hentig N, Carlebach A, Gute P, et al. A comparison of the steady-state pharmacokinetics of nevirapine in men, nonpregnant women and women in late pregnancy. Br J Clin Pharmacol. 2006;62:552-559.
31. Lyons FE, Coughlan S, Byrne CM, et al. Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. AIDS. 2005;19:63-67.
32. van Heeswijk RP, Khaliq Y, Gallicano KD, et al. The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum. Clin Pharmacol Ther. 2004;76:588-597.
33. Hirt D, Treluyer JM, Jullien V, et al. Pregnancy-related effects on nelfinavir-M8 pharmacokinetics: a population study with 133 women. Antimicrob Agents Chemother. 2006;50:2079-2086.
34. Nellen JF, Schillevoort I, Wit FW, et al. Nelfinavir plasma concentrations are low during pregnancy. Clin Infect Dis. 2004;39:736-740.
35. Schuurman R, Nijhuis M, van Leeuwen R, et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis. 1995;171:1411-1419.
36. van der Leur MR, Burger DM, la Porte CJL, et al. A retrospective TDM database analysis of interpatient variability in the pharmacokinetics of lopinavir in HIV-infected adults. Ther Drug Monit. 2006;28:650-653.
37. Manavi K, McDonald A, Al-Sharqui A. Plasma lopinavir trough levels in a group of pregnant women on lopinavir, ritonavir, zidovudine, and lamivudine. AIDS. 2007;21:643-645.
38. Lyons F, Lechelt M, De Ruiter A. Steady-state lopinavir levels in third trimester of pregnancy. AIDS. 2007;21:1053-1054.